Vascular Responses to Arachidonic Acid in the Perfused Canine Lung
SUMMARY We compared the effects of arachidonic acid (AA), the bisenoic prostaglandin precursor, with those of prostaglandin F to (PGF*,) and norepinephrine (NE) on pulmonary vascular resistance in the isolated (in situ), perfused canine lung lobe. The isolated lobe was perfused with autologous blood or an artificial perfusate under conditions of constant flow. Lobar artery and venous pressures were constantly monitored after bolus injections of AA, PGF IO , and NE into the inflow cannula. AA (100 /ig/kg) produced a significant increase in the pressure gradient (93.3 ± 8.4%, SE) in the lobe. Similarly, PGF*, (1 M g/kg) significantly increased the pressure gradient (41.2 ± 6.5%), as did NE (1 M g/ kg, 41.6 ± 3.2%). Aspirin (25 mg/kg) completely blocked the pul-monary vascular effect of AA, but did not affect the response to PGFfe, Linoleic acid, a control fatty acid, did not produce pulmonary vasoconstriction. The pressor effect of AA was not blocked by pretreatment with phentolamine, propranolol, cyproheptadine, or atropine. The use of an artificial perfusate free of cellular elements did not prevent the vasoconstrictor action of AA. The times to onset of action of the three agents were similar, and short. These results suggest that AA is converted into vasoactive intermediates or a prostaglandin, and the vasoactive intermediates or the prostaglandin act directly on precapillary pulmonary vascular smooth muscle rather than through platelet, plasma, adrenergic, or cholinergic mechanisms. segments of the circulatory system is lacking. The specific aims of this investigation were: (1) to determine the effects of AA on the canine pulmonary circulation; (2) to determine whether the response represented a direct action of A A; and (3) to assess the role of the platelet in the cardiovascular actions of AA in light of studies which describe the platelet-aggregating potential of AA 10 " 12 and the release of vasoactive substances from platelets by AA. 13 Studies were performed on the isolated, perfused canine left lower lung lobe under conditions of constant flow.
Methods
Twenty-eight mongrel dogs, unselected as to sex or weight, were anesthetized with intravenous sodium pentobarbital (30 mg/kg) and maintained on positive-pressure ventilation (room air) by endotracheal intubation. Ventilation rate was 15/min and the tidal volume was adjusted for each dog within a range of 225-300 ml. Expiration was passive.
A thoracotomy was performed in the 4th or 5th left intercostal space. We isolated the circulation to the left lower lung lobe from the remainder of the pulmonary circulation by cannulating the lobar artery and vein with polyethylene catheters. The bronchus was left intact to maintain ventilation of the lobe. The isolated lobe was perfused with autologous citrated (10% vol/vol of 3.8% sodium citrate) blood by means of a peristaltic pump. Pulmonary venous blood was drained into an open, siliconized reservoir maintained at 37°C and was recirculated through the isolated lobe. The volume of the system was approximately 200 ml.
Mean lobar arterial and venous pressures were monitored at the inflow and outflow cannulas, respectively. Flow rate through the lobe was adjusted manually to maintain mean lobar artery pressure between 12 and 16 mm Hg. This was accomplished with a flow rate between 6 and 7 ml/kg per min. The height of the outflow cannula was adjusted to produce a mean lobar venous pressure of 0-5 mm Hg.
We recorded airway pressure, which was used as an index of airway resistance, by inserting a needle into the endotracheal tube. Systemic arterial pressure was monitored through an indwelling femoral arterial catheter. All pressures were recorded continuously with a multichannel direct-writing recorder. Additional anesthetic agent, when needed, was administered through a femoral venous catheter.
Measurements of Po a , Pco 2 , and pH were made at intervals to ensure that ventilation and perfusion were adequate. The ranges of these were: Po 2 , 118-123 mm Hg; Pco,, 22-29 mm Hg; and pH, 7.40-7.47.
Arachidonic acid (5,8,11,14-eicosatetraenoic acid, >99% pure and obtained from porcine liver) and linoleic acid ( > 9 9 % pure) were obtained from Sigma. The sodium salts of these acids were prepared by dissolving them in 100 mM sodium carbonate with constant stirring under nitrogen, in the absence of light. The solutions were prepared daily and were used only if they were clear.
Prostaglandins (tromethamine salts) were supplied by Upjohn. Saline solutions of the prostaglandins were made daily from stock ethanol solutions. The sodium salt of acetylsalicylic acid (Merck) was prepared in modified Tyrode's solution and the pH was adjusted to 7.35 with sodium hydroxide. Norepinephrine (norepinephrine bitartrate, Levophed) was diluted in normal saline (75 /ig/ml). a-Adrenergic blockade was achieved with phentolamine (Regitine) at doses of 100-200 /ig/kg (7.5-15 /ig/ml of blood in the system). /3-Adrenergic antagonism was achieved with propranolol hydrochloride (Inderal), 100 /ig/kg (7.5 jig/ml of blood in the system). Cyproheptadine (Periactin), an antihistamine and antiserotonin agent, was used at a dose of 55 jig/kg (4 /ig/ml of blood in the system). Atropine sulfate (200 /ig/kg or 15 /ig/ml of blood) was used as an anticholinergic agent. Blockades were tested with the appropriate challenge drugs in doses of 1-5 jig/kg.
Challenge drugs and test substances were administered as bolus injections directly into the inflow cannula just proximal to the point of its insertion in the lobar artery. Injection volumes were 0.1-0.4 ml. Blocking agents were administered directly into the reservoir. Sufficient time was permitted for blockade to become effective. The system was allowed to return to control conditions after a test injection (approximately 5 minutes) before another agent was administered.
In the first series of experiments (17 animals), the pulmonary vascular effects of P G F^ (1 /ig/kg), norepinephrine (NE)(1 M g/kg)and AA (100/ig/kg) were studied in the blood-perfused, isolated lobe. In the second group (nine animals), the effects of these agents on pulmonary vascular reactivity were studied in blood-perfused lobes pretreated with aspirin (25 mg/kg). In the third group (five animals) pulmonary vascular responses to these compounds were first studied in the blood-perfused lobe and then immediately after replacement of the blood with a dextran-based artificial perfusate (Perfudex, Pharmacia) containing 2.5 mM CaCl 2 and 25 mM NaHCO 3 .
For statistical analysis of the data obtained, we used Student's /-test. Significance was set at the 0.05 level.
Results

RESPONSES OF BLOOD PERFUSED LOBES TO AA
Dose-response relationships for AA were established in the blood-perfused lung. The pressor response to AA showed a nearly linear relationship up to a dose of 150 /ig/kg. The threshold dose for this system was between 1 and 10 jig/kg. On the basis of these results, a dose of 100 /ig/kg of AA was used in all subsequent studies on isolated lobes. This dose resulted in a reproducible pressor response, from which recovery occurred within 5 minutes.
Through trial, we selected a dose of PGF t o of 1 /ig/kg as one which elicited a reproducible pulmonary pressor response. Since a dose of NE of 1 /ig/kg produced an equipressor response, this dose was continued throughout this study. Recovery from the pressor responses to both agents was complete in 5 minutes. Figure remained stable, indicating that there was no significant transfer of AA from the isolated lobe circulation into the systemic circulation. PGFj,, and NE also produced pressor responses in the isolated lobe: these were 41.2 ± 6.5% and 41.6 ± 3.2%, respectively, at a dose of 1 Mg/kg-Lobar vein, airway, and systemic arterial pressures were unchanged in both cases. The percentage changes in pulmonary artery pressure caused by AA, PGFjo and NE are summarized in Figure 2 .
ASPIRIN BLOCKADE
The tracing shown in Figure IB demonstrates the effects of pretreatment with aspirin on the pulmonary vascular response to AA. Aspirin did produce a small reduction (1 mm Hg) in baseline perfusion pressure in many preparations. The pulmonary pressor response to AA was completely eliminated in every preparation pretreated with aspirin. In most cases a slight reduction (3-4 mm Hg) in pulmonary artery pressure occurred within 6 seconds after administration of AA. Comparable changes in pulmonary artery pressure were produced by the control fatty acid, linoleic acid; this finding suggests that this was a nonspecific effect of fatty acid in the presence of this anti-inflammatory agent.
Responses to PGFa, and NE were not blocked by aspirin (Fig. 2) . The response to PGFj,, was essentially unchanged (44.8 ± 7.4%) but the response to NE was diminished significantly (18.7 ± l.C OTHER BLOCKING AGENTS Phentolamine, propranolol, atropine, and cyproheptadine were tested and none blocked or attenuated the pulmonary vascular response to AA.
ARTIFICIAL PERFUSION
During perfusion of the isolated lobe with an artificial perfusate free of cellular elements, the pulmonary pressor response to AA was as great (98.4 ± 31.6%) as in the blood-perfused lobe. The pulmonary vascular response to NE, 1 /xg/kg, was also unaltered by substitution of the artificial perfusate but the pressor effect of PGFJQ was diminished significantly to 10.0 ± 0.95%.
TIME OF ACTION RELATIONSHIPS
The times to onset of action for the substances were quite similar and rapid (mean, 5.5-7 seconds). This time was significantly greater (mean, 12 seconds) only for PGF*, in the artificially perfused lobe. The time to peak effect of each substance was similar between groups (mean, 21-31 seconds) except for AA (mean, 59 seconds) and PGF t o (mean, 45 seconds) in the lobe pretreated with aspirin. Duration of response (not shown here) was variable. In all cases, this did not exceed 5 minutes.
Discussion
In contrast to its systemic hypotensive effect, AA produced a rapid and marked increase in pulmonary artery VOL. 38, No. 3, MARCH 1976 pressure in the isolated blood-perfused dog lung lobe. This dose-related increase in pressure gradient occurred in the presence of constant flow and indicates that the rise in pressure was the direct result of an increase in pulmonary vascular resistance. The characteristics of this response were similar to those obtained with much smaller doses of PGF 2a and NE. The times to onset and peak action of each of the agents were very similar; this finding strongly suggests a direct action of both AA and P G F^. However, the pressor action of AA was blocked by aspirin; this indicates that biosynthetic conversion of AA to endoperoxides, prostaglandins, or other products is necessary for its vascular action. Hamberg and Samuelsson 8 demonstrated that conversion of AA into polar derivatives in a sheep seminal vesicle preparation was complete within 15 seconds, but formation of PGE 2 (measured indirectly) was complete only after 2 minutes. Moreover, Hamberg and Samuelsson 14 recently reported that administration of AA to the isolated artificially perfused guinea pig lung yielded only approximately 3% PGE 2 and 5% PGFto and more than 90% of other non-prostanoate compounds. In a later report 15 Hamberg and co-workers showed that biosynthesized endoperoxide prostaglandin intermediates had potent smooth muscle-stimulating abilities, both in vitro and in vivo.
These data, in conjunction with the rapid onset of action of AA in the lung lobe, suggest that prostaglandin intermediates are the agents responsible for the pulmonary pressor response. Conversion of AA into PGFfc, may contribute to this response, although the time for synthesis of P G Fŝ eems to be greater than the 6-second time to onset of AA action.
Our results with PGFj,, compare favorably with the results of studies by others on dogs and other species. 1 ' *• Lonigro and Dawson 16 reported that PGF t o exerts most of its effect on pulmonary vessels upstream to the capillaries and that degradation of PGF t o seems to be downstream from the site of action. In the present study, the times to onset of action of both AA and PGFj,, were identical, and strongly suggest that the sites of action are the small pulmonary arteries.
The decreased pressor response to NE in the presence of aspirin cannot be adequately explained on the basis of our data. However, Kadowitz and others" 1 18 have shown that F series prostaglandins in subvasoactive doses increase vascular reactivity to NE. In addition, NE has been shown to cause the release of prostaglandins from several tissues. 19 Either of these mechanisms might account for this decreased pressor response to NE, since generation of endogenous prostaglandins would be blocked by aspirin pretreatment with aspirin.
Experiments with the other blocking agents demonstrate that a-and £-adrenergic, cholinergic, and serotonin receptors do not mediate the response to the active compounds synthesized from AA. Rather, other receptor sites are involved in the response to these vasoactive compounds.
Silver and colleagues" demonstrated that a large dose of A A administered to rabbits intravenously produced death as a result of extensive blockage of the pulmonary circulation by platelet aggregates. No measurements of pulmonary artery pressure were made in these experiments. To rule out mechanical obstruction of small pulmonary vessels as the mechanism responsible for the pulmonary pressor response in our experiments, the isolated lobe was perfused with an artificial perfusate free of cellular elements. The pulmonary vascular responses to A A and NE were not significantly different when a perfusate free of cellular elements was used. Mechanical obstruction did not account for the rise in pulmonary artery pressure. Moreover, conversion of AA into active intermediates does not require the presence of platelets or other blood cellular elements. Other tissues, such as vascular endothelium, 20 must be a source of prostaglandin synthetase for the conversion of AA into a cascade of vasoactive compounds.
An adequate explanation for the diminished response to PGFfc, during use of an artificial perfusate is lacking. Binding of PGF20 to the dextran base, or absence of a necessary blood component for its action, could explain the reduced responsiveness in this artificial system. In addition, PGFjo may be metabolized by erythrocytes to the potent, smooth muscle-stimulating 15-keto PGFj,,. 21 -22 In the absence of erythrocytes this prostaglandin metabolite may not be formed.
